🔎 Trials Near Me

Beranda › Glioma Pontin Intrinsik Difus › Florida

Uji klinis Glioma Pontin Intrinsik Difus di Florida

7 studi untuk Glioma Pontin Intrinsik Difus mencari peserta di lokasi di Florida.

Kota di Florida

Teks studi resmi (Bahasa Inggris)

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

  • Nicklaus Children's Hospital, Miami
Menerima pesertaFase 2
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT06838676

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Johns Hopkins All Children's Hospital, St. Petersburg
Menerima pesertaFase 1/2
12 Months – 21 Years · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04870944

Targeted Pediatric High-Grade Glioma Therapy

  • University of Miami, Miami
Menerima pesertaStudi observasional
12 Months – 39 Years · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT05839379

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

  • University of Florida, Gainesville
  • Nicklaus Children's Hospital, Miami
  • Arnold Palmer Hospital for Children, Orlando
  • dan 1 lainnya
Menerima pesertaFase 1/2
Hingga usia 26 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06465199

Study of Olutasidenib and Temozolomide in HGG

  • University of Miami Hospital and Clinics, Miami
Menerima pesertaFase 2
Usia 12 hingga 39 · Semua jenis kelamin · Diperbarui 1 Sep 2026 · NCT06161974

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  • Nicklaus Children's Hospital, Miami
Menerima pesertaFase 2
Usia 3 hingga 39 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05096481

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

  • Jackson Memorial Hospital, Miami
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 8 Des 2025 · NCT05956821

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.